SCHEMBL20157679

SCHEMBL20157679

CCS(=O)(=O)Cc1ccc(C(=O)c2ccc(F)c(OC)c2)c(Br)c1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.40
TAS2R14 Q9NYV8 1/20 0.39
ACHE P22303 2/20 0.38
CYP1A2 P05177 2/20 0.37
CYP2C19 P33261 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
TSHR P16473 1/20 0.37
CYP2D6 P10635 1/20 0.36
HPGD P15428 1/20 0.36
MCHR1 Q99705 1/20 0.36
PDF Q9HBH1 1/20 0.36
ROCK2 O75116 1/20 0.36
ROCK1 Q13464 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21352105 0.91 ACHE (0.47) ALDH1A1TAS2R14ACHECYP1A2CYP2C19
SCHEMBL21351917 0.89 ALDH1A1 (0.40) ALDH1A1TAS2R14ACHECYP1A2CYP2C19
SCHEMBL20157485 0.88 ALDH1A1 (0.41) ALDH1A1ACHECYP1A2CYP2C19CYP3A4
SCHEMBL21557859 0.87 ALDH1A1 (0.40) ALDH1A1ACHECYP1A2CYP2C19CYP3A4
SCHEMBL20157608 0.85 ALDH1A1 (0.44) ALDH1A1TAS2R14ACHECYP1A2CYP2C19
SCHEMBL20158044 0.83 NPC1 (0.35) ALDH1A1ACHEMAPT
SCHEMBL20157411 0.82 NPC1 (0.48) ACHEPDFMAPTSMN1; SMN2RXFP1
SCHEMBL20157681 0.82 ALDH1A1 (0.40) ALDH1A1ACHECYP1A2CYP2C19CYP3A4
SCHEMBL20157579 0.82 TP53 (0.38) ALDH1A1MAPTSMN1; SMN2
SCHEMBL20158025 0.82 NPC1 (0.42) MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) 2019-09-19 US disclosed
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) 2019-09-19 US disclosed
EP-3539960-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) 2019-09-18 EP disclosed
EP-3539960-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) 2019-09-18 EP disclosed
WO-2018086605-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF 山东罗欣药业集团股份有限公司 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF MYC, BRD1, BRD3 ALDH1A1 4457/4885TAS2R14 2078/4885ACHE 4557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.